Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -39.49% | -54.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -39.49% | -54.61% | |||
| Cost of Revenue | -50.54% | 0.13% | |||
| Gross Profit | 51.61% | -13.45% | |||
| SG&A Expenses | 52.55% | 20.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.87% | 6.93% | |||
| Operating Income | 10.24% | -16.18% | |||
| Income Before Tax | -9.39% | -24.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.39% | -24.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.39% | -24.07% | |||
| EBIT | 10.24% | -16.18% | |||
| EBITDA | 11.66% | -18.35% | |||
| EPS Basic | -9.36% | -23.75% | |||
| Normalized Basic EPS | 21.54% | -23.72% | |||
| EPS Diluted | -9.36% | -23.75% | |||
| Normalized Diluted EPS | 21.54% | -23.72% | |||
| Average Basic Shares Outstanding | 0.02% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
